oral glp 1 inhibitors Lesson: Semaglutide: A New GLP-1 Receptor Agonist Product for the Treatment of Type 2 Diabetes US FDA accepts Novo Nordisk's
Description
Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) are currently underway and will provide the definitive comparison data
However, sustained weight loss is difficult for many patients
A major concern is maintaining proper nutrition
The purpose of this chapter is to provide the healthcare practitioner with detailed information on the existing oral and injectable (non-insulin) pharmacological options available for the treatment of patients with T2DM
